Opinion|Videos|January 13, 2025
The Role of Posttransplant Cyclophosphamide in Patients With cGVHD
Author(s)Sergio A. Giralt, MD
Sergio A. Giralt, MD, discusses how he uses cyclophosphamide to treat patients with chronic graft-vs-host disease (cGVHD), particularly in specific cases where other therapies may not be effective. He reviews the study design and methods of recent research investigating cyclophosphamide in cGVHD management, emphasizing its importance in optimizing treatment strategies.
Advertisement
Video content above is prompted by the following:
- Which patients with chronic graft-vs-host disease (cGVHD) do you treat with cyclophosphamide in your clinical practice?
- What were this abstract’s study design and methods, and why was it important to investigate for cGVHD management?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss
2
Measles Cases Climb to 2000 in the US, Increasing Cases Year Over Year
3
Emerging Data Suggest Survodutide Targets Liver Fat More Rapidly Than Weight Loss: Lee Kaplan, MD, PhD
4
Survodutide Normalizes Liver Fat in 61% of Patients With MASLD in Phase 3 Trial: Lee Kaplan, MD, PhD
5